CN115151569B - Cd163抗体或结合蛋白 - Google Patents

Cd163抗体或结合蛋白

Info

Publication number
CN115151569B
CN115151569B CN202080097372.4A CN202080097372A CN115151569B CN 115151569 B CN115151569 B CN 115151569B CN 202080097372 A CN202080097372 A CN 202080097372A CN 115151569 B CN115151569 B CN 115151569B
Authority
CN
China
Prior art keywords
gly
ser
ala
heavy chain
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080097372.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN115151569A (zh
Inventor
C·欧文
H·A·本朝晖
C·泰特伯卡德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eco Animal Health Ltd
Original Assignee
Eco Animal Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eco Animal Health Ltd filed Critical Eco Animal Health Ltd
Priority to CN202610134672.4A priority Critical patent/CN121873247A/zh
Publication of CN115151569A publication Critical patent/CN115151569A/zh
Application granted granted Critical
Publication of CN115151569B publication Critical patent/CN115151569B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080097372.4A 2019-12-24 2020-12-24 Cd163抗体或结合蛋白 Active CN115151569B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202610134672.4A CN121873247A (zh) 2019-12-24 2020-12-24 Cd163抗体或结合蛋白

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1919294.7 2019-12-24
GBGB1919294.7A GB201919294D0 (en) 2019-12-24 2019-12-24 Antibodies or binding proteins
PCT/GB2020/053370 WO2021130502A1 (en) 2019-12-24 2020-12-24 Cd163 antibodies or binding proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610134672.4A Division CN121873247A (zh) 2019-12-24 2020-12-24 Cd163抗体或结合蛋白

Publications (2)

Publication Number Publication Date
CN115151569A CN115151569A (zh) 2022-10-04
CN115151569B true CN115151569B (zh) 2026-05-01

Family

ID=69322779

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080097372.4A Active CN115151569B (zh) 2019-12-24 2020-12-24 Cd163抗体或结合蛋白
CN202610134672.4A Pending CN121873247A (zh) 2019-12-24 2020-12-24 Cd163抗体或结合蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202610134672.4A Pending CN121873247A (zh) 2019-12-24 2020-12-24 Cd163抗体或结合蛋白

Country Status (13)

Country Link
US (1) US20230203185A1 (enExample)
EP (1) EP4081542A1 (enExample)
JP (1) JP7702952B2 (enExample)
KR (2) KR20260098023A (enExample)
CN (2) CN115151569B (enExample)
BR (1) BR112022012362A2 (enExample)
CL (1) CL2022001706A1 (enExample)
CO (1) CO2022010294A2 (enExample)
DO (2) DOP2022000136A (enExample)
GB (1) GB201919294D0 (enExample)
MX (1) MX428622B (enExample)
PE (1) PE20230384A1 (enExample)
WO (1) WO2021130502A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12098400B2 (en) * 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
GB202214979D0 (en) * 2022-10-11 2022-11-23 Eco Animal Health Ltd Binding protein
JP2026519901A (ja) * 2023-01-27 2026-06-19 ヴィーアイビー ヴィーゼットヴィー Ｃｄ１６３結合複合体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119569865B (zh) * 2024-12-20 2025-10-10 西北农林科技大学 一种防治猪繁殖与呼吸障碍综合征病毒感染的混合制剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076501A2 (en) * 2001-03-26 2002-10-03 Hemosol Inc. Blood cell production via activation of the hemoglobin scavenger receptor
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20160158368A1 (en) * 2014-10-31 2016-06-09 Therapure Biopharma Inc. Methods and compositions for the treatment of histiocytosis
HRP20240908T1 (hr) * 2015-08-06 2024-10-25 The Curators Of The University Of Missouri Svinja i stanice otporne na virus reproduktivnog i respiratornog sindroma svinja (prrsv) koje imaju modificirane cd163 gene
US11160260B2 (en) * 2018-04-17 2021-11-02 The Curators Of The University Of Missouri Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Expression of porcine CD163 on monocytes/macrophages correlates with permissiveness to African swine fever infection;C. S´anchez-Torres;Arch Virol;20031231;第148卷(第12期);2307-2323 *

Also Published As

Publication number Publication date
JP2023508674A (ja) 2023-03-03
CO2022010294A2 (es) 2022-10-31
US20230203185A1 (en) 2023-06-29
PE20230384A1 (es) 2023-03-06
CN115151569A (zh) 2022-10-04
KR20260098023A (ko) 2026-06-25
BR112022012362A2 (pt) 2022-09-06
CN121873247A (zh) 2026-04-17
MX2022007957A (es) 2022-10-07
WO2021130502A1 (en) 2021-07-01
CL2022001706A1 (es) 2023-05-26
DOP2022000136A (es) 2022-11-30
DOP2025000290A (es) 2026-02-26
KR20220119147A (ko) 2022-08-26
CA3162664A1 (en) 2021-07-01
MX428622B (es) 2025-11-13
EP4081542A1 (en) 2022-11-02
JP7702952B2 (ja) 2025-07-04
GB201919294D0 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
JP7702952B2 (ja) Ｃｄ１６３抗体または結合タンパク質
US10906965B2 (en) Methods of treating autoimmune disease or chronic inflammation wtih antibodies that bind peptidoglycan recognition protein 1
CN115768790A (zh) 针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人单克隆抗体
US20240376180A1 (en) Human recombinant monoclonal antibody against sars-cov-2 spike glycoprotein
TW202144405A (zh) 抗新型冠狀病毒(SARS-CoV-2)之新穎單株抗體及其應用
WO2021228904A1 (en) Neutralizing antibodies binding to the spike protein of sars-cov-2 suitable for use in the treatment of covid-19, compositions comprising the same and uses thereof
AU2015239606C1 (en) Antibodies against HPA-1a
CN115315442B (zh) Sars-cov-2抗体及其应用
US20260085129A1 (en) Cd163 binding protein
US20230065377A1 (en) Human antibodies to alphaviruses
WO2021195385A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
Halfmann et al. Potent bivalent nanobody constructs that protect against the SARS-CoV-2 XBB variant
CA3162664C (en) Cd163 antibodies or binding proteins
CN116693671A (zh) 新型冠状病毒中和性抗体及其制备方法与用途
CA2954687A1 (en) Substances and methods for the use in prevention and/or treatment in huntington's disease
Thueng-In et al. Cell-penetrating porcine single-chain antibodies (transbodies) against nonstructural protein 1β (NSP1β) of porcine reproductive and respiratory syndrome virus inhibit virus replication: K. Thueng-in et al.
EP4532009A1 (en) Antibodies to necrotic enteritis b-like toxin
CN116419972A (zh) 抗SARS-CoV-2抗体及其应用
US20250304659A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 1 (SARS-CoV-1)
WO2023178182A1 (en) Compositions and methods for detection and treatment of coronavirus infection
US20230365658A1 (en) REPAIRED THERAPEUTIC AND PROPHYLACTIC ANTIBODIES AGAINST SARS-CoV-2 VARIANTS
Thueng-in et al. Cell-penetrating porcine single-chain antibodies (transbodies) to nonstructural protein 1β (NSP1β) of PRRSV inhibit the virus replication
Coelho Isolation of human recombinant antibodies anti-SARS-CoV-2 by synthetic methods
WO2024196463A2 (en) Broadly neutralizing human monoclonal antibodies that target the sars-cov-2 receptor binding domain (rbd)
CN116547004A (zh) SARS-CoV-2结合肽

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant